Search research articles
Contact Us
Filters
Showing results (191-200 of 276) with videos related to
Page
of 28
Sort By:
Blood Advances
|
January 17, 2024
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
Gail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, et al.
Blood Advances
|
July 12, 2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
Sumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
The Lancet. Haematology
|
March 9, 2020
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
Eytan M Stein, Amir T Fathi, Courtney D DiNardo, et al.
Cell Reports
|
December 3, 2015
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species
Hongliang Zong, Alexander Gozman, Eloisi Caldas-Lopes, et al.
Blood Advances
|
April 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
Courtney D DiNardo, Gail J Roboz, Justin M Watts, et al.
Blood Neoplasia
|
September 8, 2025
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
Ahmed Aribi, Gabriel N Mannis, Yazan F Madanat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H Wei, Stephen A Strickland, Jing-Zhou Hou, et al.
Blood Advances
|
October 22, 2020
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response
Ok-Kyong Chaekal, Andromachi Scaradavou, Emeline Masson Frenet, et al.
Journal of Hematology & Oncology
|
August 29, 2021
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
Farhad Ravandi, Gail J Roboz, Andrew H Wei, et al.
Leukemia & Lymphoma
|
January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis
Elizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
Page
of 28
Search research articles
Search
Showing results (191-200 of 276) with videos related to
Sort By:
Page
of 28
Blood Advances
|
January 17, 2024
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
Gail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, et al.
Blood Advances
|
July 12, 2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
Sumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
The Lancet. Haematology
|
March 9, 2020
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
Eytan M Stein, Amir T Fathi, Courtney D DiNardo, et al.
Cell Reports
|
December 3, 2015
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species
Hongliang Zong, Alexander Gozman, Eloisi Caldas-Lopes, et al.
Blood Advances
|
April 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
Courtney D DiNardo, Gail J Roboz, Justin M Watts, et al.
Blood Neoplasia
|
September 8, 2025
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
Ahmed Aribi, Gabriel N Mannis, Yazan F Madanat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H Wei, Stephen A Strickland, Jing-Zhou Hou, et al.
Blood Advances
|
October 22, 2020
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response
Ok-Kyong Chaekal, Andromachi Scaradavou, Emeline Masson Frenet, et al.
Journal of Hematology & Oncology
|
August 29, 2021
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
Farhad Ravandi, Gail J Roboz, Andrew H Wei, et al.
Leukemia & Lymphoma
|
January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis
Elizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
Page
of 28